Home  >  Products  >  DLC1 (deleted in liver cancer 1) Blocking Peptide (100ug)
DLC1 (deleted in liver cancer 1) Blocking Peptide (100ug)

DLC1 (deleted in liver cancer 1) Blocking Peptide (100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-DLC1 antibody (Catalogue #: ARP52138_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Presku: AAP52138
Size: 100 ug
Weight: 52kDa
Gene: 10395
Format: Lyophilized powder
Target: This gene is deleted in the primary tumor of hepatocellular carcinoma. It maps to 8p22-p21.3, a region frequently deleted in solid tumors. It is suggested that this gene is a candidate tumor suppressor gene for human liver cancer, as well as for prostate, lung, colorectal, and breast cancers. DLC1 functions as a GTPase-activating protein specific for Rho and an activator of PLCD1 in vivo and induces morphological changes and detachment through cytoskeletal reorganization.
Alternative names: ARHGAP7, FLJ21120, HP, STARD12, p122-RhoGAP
See Full Product Listings >